# Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

> **NCT00883480** · NA · COMPLETED · sponsor: **Spanish Lung Cancer Group** · enrollment: 153 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00883480
- **Lead sponsor:** Spanish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-01
- **Final completion:** 2008-11
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883480, "Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00883480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*